Alternatively for mipdatabase quick searches go here

Custom Search

Abstract: More and more disputes have happened to confront us continuously since the separation of Japanese (wild) honeysuckle flower in Chinese Pharmacopoeia in 2005. The state pharmacopeia committee decided to separate Japanese (wild) honeysuckle flower into two species for japanese (wild) honeysuckle flower, but didn't define their the convincing reasons still did not provide to us as a result that two medicines are not described the differences in natural properties, efficiency and indication, usage and dosage, as well as not given a resolving method and specific solution. It was known for us that in the history of traditional Chinese medicine (TCM), the phenomenenphenomena of the "one drug from multi-species" and "one species for multi-drug" are very ordinary things were ubiquitous. Whether separation of the drug species are separated shall be decided to by clinical efficiency. Through Chinese pharmacopoeia (2015 edition) issue of Chinese Pharmacopoeia the 2015 issue of the Chinese Pharmacopoeia, we still cannot find a scientific solution for the dispute of for Japanese (wild) honeysuckle flower, perhaps because of insufficient reorganization of TCM clinical medication regularities, such as "treatment of different diseases with same drug", "treatment of the same disease with different drugs" and "treatment of the same syndrome with multi-prescriptions", and "one prescription treating multiple syndromes"; lack of in-depth analysis for multicomponent TCM compounds and autonomisation of "supermolecular template" for organs and meridians; less attention to the advance of efficacy and safety evaluation technologies for multi-component TCM compounds; impacts from the medication mode of "one ingredient one composition-one effect"; as well as insufficient research methods for bioequivalent evaluation in preclinic and clinic studies. The dispute for species combination or separation for Japanese (wild) honeysuckle flower was apparently caused by regional economy, drug biological equivalent of efficacy and safety, but arising from clinical principles for systematical syndrome treatment with TCM, or concepts in the treatment of diseases with TCM or western medicines. This paper focused on current studies on Japanese (wild) honeysuckle flower in the combination with TCM clinical medication regularities, such as "treatment of different diseases with same drug", "treatment of the same disease with different drugs" and "treatment of the same syndrome with multi-prescriptions", and "one prescription treating multiple syndromes", expounded the specific pharmacological regularity of "heterogeneous equivalence"o f Japanese (wild) honeysuckle flower, and put forward methods for studying bioequivalence of Japanese (wild) honeysuckle flower, in order to solve the combination and separation of Japanese (wild) honeysuckle flower and lay a foundation for promoting the development of Chinese herbal medicine industry.
Author keywords: Japanese (wild) honeysuckle flower, heterogeneous bioequivalence, supermolecular chemistry, imprinting template, basic theory of traditional Chinese medicine, Qi chromatography, pharmacology of traditional Chinese medicine, modernization of traditional Chinese medicine, meridian and organs, molecular topology